Methods of targeting of viral entry
AssigneesPresident and Fellows of Harvard College, Children's Medical Center Corporation
InventorsJohn A. T. Young, Richard C. Mulligan, Sophie Snitkovsky, Thomas M. J. Niederman
Life of this patent
Estimating the term…
Abstract
Novel targeting methods of viral entry are disclosed herein.
Claims28
A method of targeting viral entry comprising combining:
- a) a target cell;
- b) a viral vector which has a targeting molecule which binds to a surface protein on said target cell;
- and
- c) a soluble viral receptor-ligand fusion molecule, wherein the soluble viral receptor moiety is an extracellular domain of a viral cellular receptor or a functional derivative thereof and the ligand moiety binds to a cell-type specific cellular receptor wherein viral entry is targeted.
A method of targeting viral entry comprising combining:
- a) a target cell;
- b) a viral vector which has a targeting molecule which binds to a surface protein on said target cell;
- and
- c) a soluble viral receptor, wherein the soluble viral receptor is an extracellular domain of a viral cellular receptor or a functional derivative thereof wherein viral entry is targeted.
A method for delivering a viral vector to a cell comprising contacting a target cell with:
- a) a viral vector which has a targeting molecule which binds to a surface protein on said target cell;
- and
- b) a soluble viral receptor-ligand fusion molecule, wherein the soluble viral receptor moiety is an extracellular domain of a viral cellular receptor or a functional derivative thereof and the ligand moiety binds to a cell-type specific cellular receptor wherein a viral vector is delivered to a cell.
A method for delivering a viral vector to a cell comprising contacting a target cell with:
- a) a viral vector which has a targeting molecule which binds to a surface protein on said target cell;
- and
- b) a soluble viral receptor, wherein the soluble viral receptor is an extracellular domain of a viral cellular receptor or a functional derivative thereof wherein a viral vector is delivered to a cell.
A method of targeting retroviral entry comprising combining:
- a) a target cell;
- b) a retroviral vector which has a targeting molecule which binds to a surface protein on said target cell;
- and
- c) a soluble retroviral receptor-ligand fusion molecule, wherein the soluble retroviral receptor moiety is an extracellular domain of a retroviral cellular receptor or a functional derivative thereof and the ligand moiety binds to a cell-type specific cellular receptor wherein retroviral entry is targeted.
A method of targeting retroviral entry comprising combining:
- a) a target cell;
- b) a retroviral vector which has a targeting molecule which binds to a surface protein on said target cell;
- and
- c) a soluble retroviral receptor, wherein the soluble retroviral receptor is an extracellular domain of a retroviral cellular receptor or a functional derivative thereof wherein retroviral entry is targeted.
A method for delivering a retroviral vector to a cell comprising contacting a target cell with:
- a) a retroviral vector which has a targeting molecule which binds to a surface protein on said target cell;
- and b) a soluble retroviral receptor-ligand fusion molecule, wherein the soluble retroviral moiety is an extracellular domain of a retroviral cellular receptor or a functional derivative thereof and the ligand moiety binds to a cell-type specific cellular receptor wherein a retrovirus is delivered to a cell.
A method for delivering a retroviral vector to a cell comprising contacting a target cell with:
- a) a retroviral vector which has a targeting molecule which binds to a surface protein on said target cell;
- and
- b) a soluble retroviral receptor, wherein the soluble retroviral receptor is an extracellular domain of a retroviral cellular receptor or a functional derivative thereof wherein the retrovirus is delivered to a cell.
Dependencies are inferred from the claim text.